Skip to content
Catalyst
PANSS negative subscale score

1 finding · 1 compound · by evidence strength. No dose is advised.

Fig. 2 PANSS negative subscale score1 compound outer ring on requestSelected PANSS negative subscale score · centre
×1.60
Labels
Measured outcomeInspector

PANSS negative subscale score

Findings drawn, by strength

1finding · 1 compound

  • Very limited1
Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

Compound lowersFindingsStrongest
1
Very limited

Not pooled · no summary effect · point at a mark · Tab, then the arrow keys

Reported to move it1 finding

  1. GlycineMoved: lowersEvidence: Very limitedPaper: PMID 98922531999
    Who
    Twenty-two treatment-resistant schizophrenic patients with enduring negative symptoms, glycine added to ongoing antipsychotic medication in a double-blind placebo-controlled crossover
    Dose studied
    0.8 g/kg per day glycine added to ongoing antipsychotic medication

    Glycine administration resulted in (1) a significant (P<.001) 30%+/-16% reduction in negative symptoms, as measured by the PANSS, and (2) a significant (P<.001) 30%+/-18% improvement in the BPRS total scores.”

    Quoted verbatim from Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.crossoverPermalink

How it is measured

Sum of the seven negative scale items (N1 to N7: blunted affect, emotional withdrawal, poor rapport, passive or apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, and stereotyped thinking) of the PANSS (Kay, Fiszbein and Opler 1987), each rated 1 to 7, summed to 7 to 49; higher is worse.

Measured, with no finding

1 measurement

Show what was measuredHide what was measured
  • PANSS negative subscale score

    d=0.68

    Not recorded as a finding: The only sentence names two subscales together and names no comparator, so it does not support one claim on its own (one outcome per quote).

    Statistically significant improvement was also evident for the PANSS negative (d=0.68) and general psychopathology (d=0.84) subscales (Table 2).

    PMID 28289280 · one of two readings recorded this

Papers about it

As an endpoint3

Show the papersHide the papers
  • Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.

    Molecular psychiatry2018PMID 28289280Via: named in the paper, as read

  • Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.

    Psychiatry and clinical neurosciences2014PMID 24548129Via: named in the paper, as read

  • Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

    Archives of general psychiatry1999PMID 9892253Via: named in the paper, as read

Newest

  • Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial.

    Molecular psychiatry2018PMID 28289280As an endpoint

  • Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial.

    Psychiatry and clinical neurosciences2014PMID 24548129As an endpoint

  • Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

    Archives of general psychiatry1999PMID 9892253As an endpoint